As a consequence, tyrosine kinase inhibitors (TKIs) targeting EGFR (gefitinib, erlotinib and afatinib) have emerged as effective drugs for therapy of NSCLC [5–7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.